Elisabet Lund Appointed CFO of VirtaMed

The new appointment, effective November 15, supports the company’s continued growth and expansion in the global digital surgery market

VirtaMed, the Zurich-based world leader in surgical simulation, has announced that Elisabet Lund has been appointed as Chief Financial Officer of the company, effective November 15, 2021.

Elisabet Lund – a former CFO for the Swedish vascular simulation company Mentice AB – brings over two decades of experience in senior finance and leadership to VirtaMed’s executive team.

“We are extremely pleased to welcome Elisabet to VirtaMed and benefit from her familiarity with the rapidly growing medical education industry,” said Dr. Raimundo Sierra, founder and CEO of VirtaMed. “Elisabet is the perfect fit to build on our strong financial position and support our team as it continues to develop.”

Elisabet Lund holds a Bachelor’s degree in Business Administration from the University of Gothenburg. Among her many accomplishments with Mentice AB includes listing the company on the Nasdaq First North Premier Growth Market in 2019.

“I am very excited about joining VirtaMed and look forward to the opportunity to work with a highly committed and professional team and to be a part of VirtaMed’s journey ahead,” said Lund.

SourceVirtaMed

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version